Opinion

Video

Personalizing ADC Therapy in mBC Based on Patient Characteristics and Prior Therapies

Author(s):

Heather Moore, BCOP, CPP, PharmD, Jodi Taraba, PharmD, MS, BCOP

Panelists discuss how patient characteristics significantly impact antibody-drug conjugate (ADC) therapy selection, with key factors including the presence and location of brain metastases (due to blood-brain barrier penetration), organ function and comorbidities affecting toxicity risks, and prior treatment history that may influence both efficacy and safety. Treatment decisions require careful individualization.

Video content above has been prompted by the following:

  • How do patient characteristics (eg, brain metastases, other comorbidities, prior therapies) influence ADC therapy selection?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
3 experts are featured in this series.
Related Content
A middle-aged breast cancer woman with clothing around her head effected from chemo therapy sitting on wheel chair and hold hand of her daughter with hope and trust in love. | Image Credit: Bangkok Click Studio | stock.adobe.com
September 4th 2025

Dual Inhibition of KAT6A/B and Menin: A Promising Strategy for ER+ Breast Cancer

Danielle Valletti, Assistant Editor
pharmacy focus oncology edition
September 4th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Breast cancer and SERDs -- Image credit: Phongsakorn | stock.adobe.com
September 4th 2025

Oral SERDs in Breast Cancer: Imulnestrant and Elacestrant

Gillian McGovern, Associate Editor
Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
September 4th 2025

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Alexandra Gerlach, Associate Editor
Ambulatory chemotherapy | Image Credit: RFBSIP | stock.adobe.com
September 4th 2025

Limited Benefit of Adjuvant Chemotherapy in Older Women With HR-Positive, HER2-Negative Breast Cancer

Danielle Valletti, Assistant Editor
Selection Considerations for Abemaciclib Versus Ribociclib in Early HR+/HER2- Breast Cancer: Efficacy, Safety, and Long-Term Outcomes
September 4th 2025

Selection Considerations for Abemaciclib Versus Ribociclib in Early HR+/HER2- Breast Cancer: Efficacy, Safety, and Long-Term Outcomes

Benjamin Gibson, PharmD, PAHM
© 2025 MJH Life Sciences

All rights reserved.